The autism biomarkers consortium for clinical trials: evaluation of a battery of candidate eye-tracking biomarkers for use in autism clinical trials.

Frederick ShicAdam J NaplesErin C BarneyShou An ChangBeibin LiTakumi McAllisterMinah KimKelsey J DommerSimone HasselmoAdham AtyabiQuan WangGerhard HellemanApril R LevinHelen SeowRaphael BernierKatarzyna CharwaskaGeraldine DawsonJames DziuraSusan FajaShafali Spurling JesteScott P JohnsonMichael MuriasCharles A NelsonMaura Sabatos-DeVitoDamla SenturkCatherine A SugarSara J WebbJames Charles McPartland

Published in: Molecular autism (2022)

All ET tasks met expectations regarding biomarker properties, with strongest performance for tasks associated with attention to human faces and weakest performance associated with biological motion preference. Based on these data, the OMI has been accepted to the FDA's Biomarker Qualification program, providing a path for advancing efforts to develop biomarkers for use in clinical trials.

Keyphrases

clinical trial
working memory
autism spectrum disorder
intellectual disability
phase ii
quality improvement
endothelial cells
open label
study protocol
tyrosine kinase